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ABSTRACT
Preeclampsia and conditions associated with impaired placental perfusion develop in almost 10% of all pregnancies. Patho-
logic angiogenesis is one of the processes observed in preeclampsia. sFlt-1, PlGF and the sFlt-1/PlGF ratio are new and 
promising angiogenesis-related biomarkers. Our paper describes the present status of, and clinical practice opportunities 
for, these factors.
According to present data, sFlt-1, PlGF and the sFlt-1/PlGF ratio are very useful tools in assessing placental angiogenesis 
abnormalities associated with preeclampsia and can be use in clinical practice.
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INTRODUCTION
Preeclampsia and conditions associated with impaired 
placental perfusion develop in almost 10% of all pregnan-
cies [1]. The last two decades have seen a 25% rise in the 
prevalence of these pathologies in the United States [2]. Ac-
cording to the statistical data, clinical syndromes developing 
secondarily to placental ischemia account for almost 50% of 
iatrogenic premature births, 50% of hospitalizations in patho-
logical pregnancy departments and 25% of intensive care 
stays among pregnant patients [3]. Every year, preeclampsia 
causes nearly 60 thousand deaths among pregnant women 
[4]. Presently, we are unable to successfully treat these condi-
tions, and the only effective therapy available is termination 
of the pregnancy. However, recent years have witnessed the 
emergence of diagnostic methods that have considerably 
improved our ability to predict pathological symptoms and 
thus the quality of our monitoring of women and fetuses.
Currently, literary sources concerned with this topic dis-
tinguish between early- and late-onset forms of preeclamp-
sia [5]. The early-onset form develops prior to 32–34 weeks 
of gestation and is definitively connected with impaired 
trophoblast invasion. The insufficient transformation of 
the spiral arteries leads to ischemia, uteroplacental com-
partment hypoxia, and subsequently, to pathological pro-
cesses such as elevated oxidative stress, inflammation or 
angiogenesis disorders arising. As a consequence of this, 
generalized endothelial damage occurs and various clini-
cal symptoms develop, such as arterial hypertension, pro-
teinuria, increased liver damage marker levels, eclampsia 
and intrauterine growth restriction [6]. The late-onset form 
of preeclampsia, which has a similar clinical presentation, 
develops after 34 weeks’ of gestation and, according to the 
current data, there is only a slightly inadequate transfor-
mation of the spiral arteries, and the main role is played 
by maternal factors, e.g. metabolic syndrome [7]. It is also 
possible that a contributing factor for the development 
of late-onset preeclampsia syndromes is patient-specific 
programmed placental senescence.
CURRENT STATUS
Formerly, preeclampsia diagnosis was mainly based on 
recognizing clinical symptoms and studying the analytical 
parameters of laboratory tests that revealed the degree 
of organ damage. However, these analytical criteria were 
frequently so ambiguous that making the right diagnosis 
was difficult and required a process of elimination, which 
took a substantial amount of time. A consequence of the 
approach was a marked delay in diagnosis and, frequently, 
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very serious consequences for the mother and her child. 
Presently, we are aiming to work out a more precise di-
agnostic process which is capable of exploring the earlier 
stages of the condition’s development. Determining the 
presence of angiogenesis disorder-related markers in the 
uteroplacental compartment is one method to achieve that 
objective. Already, fms-like tyrosine kinase (sFlt-1 — soluble 
tyrosine kinase receptor) and placental growth factor (PlGF) 
laboratory kits have been marketed. sFlt-1 is produced by 
the syncytiotrophoblast, and its concentrations are only 
a few times the concentrations of PlGF in physiological 
pregnancies [8]. In hypoxia, or impaired perfusion of the 
placenta, the trophoblast produces massive amounts of sFlt-
1, and the concentrations recorded in maternal circulation 
are at least several dozen times the levels of PlGF [9]. Such 
elevated levels of sFlt-1 have a dysfunctional effect that are 
responsible for most of the clinical and laboratory symptoms 
observed in preeclampsia [10].
PlGF has a stabilizing impact on endothelial function. 
It exerts a positive effect on, for example, placental func-
tion, but as sFlt-1 damage to the trophoblastic structures 
increases, its concentration is gradually reduced. Moreover, 
sFlt-1 is responsible for neutralizing PlGF and restricting its 
availability [11]. The situation observed under homeostatic 
conditions in normal pregnancies on the one hand, and in 
angiogenesis disorders accompanying preeclampsia on 
the other, is best represented by the diagram below (Fig. 1).
The model was modified in 2016 by proposing that 
a two-stage prediction process should be performed be-
tween 11 and 14 weeks, and between 19 and 24 gestational 
age, using MAP, UtA-PI and PlGF. Thanks to this modifica-
tion, detection rates (DR) of 75% and 85% were achieved 
for the first and second trimesters, respectively; each with 
a false positive rate (FPR) of 10% [15]. For the purposes of 
comparison, the model currently proposed by ACOG results 
in a DR of 90% with an FPR of 67% [16].
Later in the pregnancy, the highest predictive and di-
agnostic value starting from 20 weeks gestational age is 
achieved by measuring sFlt-1 and PlGF levels simultane-
ously. The sFlt-1/PlGF ratio derived from this data is consid-
ered predictive at a cut-off point of 85 [17].
At the earliest, trophoblast invasion disorders lead to 
the development of clinical symptoms after 20 weeks ges-
tational age. Research reported in the literature has shown 
that among patients with existing predictive factors for 
preeclampsia such as chronic hypertension, chronic renal 
conditions, diabetes mellitus andantiphospholipid syn-
drome, or with a history of preeclampsia, the sFlt-1/PlGF 
ratio test allows us to single out that group of patients 
who are at risk of developing a severe obstetric pathology 
at a given time. The test is similarly beneficial if conducted 
in pregnant patients who demonstrate any of the clini-
cal or laboratory symptoms of preeclampsia [18]. Positive 
sFlt-1/PlGF ratio values, from tests repeated over a period 
at precise time intervals, allow us to dispel any diagnostic 
doubts that might persist in such situations.
2015 saw the presentation of the PROGNOSIS test that 
was carried out in 30 centers around the globe and that 
included 1.050 pregnant patients with suspected preec-
lampsia who were between 24- and 37-weeks gestational 
age. The study was designed to assess the usefulness of 
sFlt-1/PlGF ratio values for a short-term prognosis, of be-
tween 1 week and 4 weeks following the emergence of 
preeclampsia. Based on the study outcomes it was found 
that ratio values of less than 38 ruled out the emergence 
of preeclampsia within the following 7 days (an NPV of 
99.3%). The study showed that in patients below 34 weeks 
gestational age, with ratio values greater than 85, and in 
those over 34 weeks gestational age, with ratio values 
greater than 110, there was a very high likelihood of them 
developing preeclampsia or another condition caused by 
an ischemic placenta.
In the high-risk cases mentioned above, the ratio values 
should be monitored and assessed for any indication of pro-
gression in the changes. In severe cases of early-onset preec-
lampsia with a ratio of > 655, and in late-onset preeclampsia 
with a ratio of > 201, there are strong implications for preg-
nancy termination within 48 hours of the test results. sFlt-
1/PlGF ratio values between 38 and 85 (110) indicate that 
Figure 1. Diagram of the balance of angiogenesis markers in normal 





Changes in the sFlt-1 and PlGF concentrations precede 
the appearance of clinical symptoms and the biochemi-
cal parameters of preeclamptic organ damage by approxi-
mately 5 to 6 weeks [13].
In diagnosing preeclampsia, PlGF can be used as early 
as the first trimester. Combining biophysical examinations 
with biochemical marker assessments has enabled the dis-
covery of an optimal model for detecting those patients 
with a higher risk of developing early-onset preeclampsia. 
This risk assessment algorithm uses the pregnant patient’s 
medical history data, mean arterial pressure (measured 
twice on both the arms — MAP), uterine arterial pulsa-
tility index, and PAPP-A and PlGF concentrations [14]. 
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there may be abnormal placental perfusion, therefore the 
authors suggest that in patients with these results prior to 
34 weeks gestational age the ratio should be monitored, and 
in patients after 34 weeks gestational age the ratio should 
be monitored, and early labor induction considered [19].
Based on present studies, in 2016 the National Institute 
for Health and Care Excellence (NICE) of the United Kingdom 
found the sFlt-1/PlGF test to be a promising tool for ruling 
out preeclampsia in pregnant patients between 20- and 
35-weeks gestational age. The Institute ruled, however, that 
there was a need for further study and that the current state 
of knowledge was insufficient for recommending the sFlt-
1/PlGF test as a routine tool in NHS practice [20].
In 2016 and 2017 more reports on the usefulness of the 
sFlt-1/PlGF ratio test for ruling out preeclampsia were pub-
lished. Zeisler et al. presented their results of a multi-center 
study, where they proved that an sFlt/PlGF ratio cut-off 
level of 38 had a negative predictive value of 99.3% [21]. In 
another study of over 4.000 pregnant women with a low risk 
of developing preeclampsia, Sovio et al. [22] found that the 
sFlt-1/PlGF ratio was very useful for detecting preeclampsia 
after 36 weeks gestational age. In addition, the same study 
found that positive ratio values in women after 28 weeks 
gestational age correlated with a direct risk of the need to 
terminate the pregnancy due to evidence of clinical preec-
lamptic features. Dragan et al. presented the results of their 
research on the sFlt-1/PlGF ratio in more than 12,000 preg-
nant patients. The researchers showed that an sFlt-1/PlGF 
ratio of 38 or less provided a certainty of 99.97% that the 
patient would not deliver her child within a week of the 
test, due to preeclampsia. Moreover, the negative predic-
tive value for a ratio of > 38 was very high, at 99.91% [23].
As mentioned above, high sFlt-1/PlGF ratio values cor-
relate positively with the manifestation of serious clinical 
symptoms necessitating pregnancy termination [18]. It has 
also been shown that higher sFlt-1 and lower PlGF con-
centrations are associated with the emergence of more 
severe clinical syndromes. In early-onset preeclampsia the 
ratio values are decidedly higher than in the late-onset 
form of this condition [24]. sFlt-1 concentrations are directly 
proportional to the severity of proteinuria and inversely 
proportional to the platelet count [25].
As the research carried out so far indicates, assessing 
angiogenesis disorder-related markers may prove to be 
a valuable support for and addition to the diagnosis of 
preeclampsia, and to the monitoring methods currently in 
use. The studies mentioned in our paper indicate clearly that 
the sFlt-1/PlGF ratio value also correlates with the severity 
of the clinical symptoms. Very high ratio values directly 
precede the emergence of symptoms necessitating preg-
nancy termination. Despite these facts, further studies are 
required before the sFlt-1/PlGF ratio can be introduced as 
an independent tool. This year has seen the publication of 
several reports that have included the sFlt-1/PlGF ratio in 
algorithms for predicting the development of early- and 
late-onset forms of preeclampsia. It has been proven pos-
sible to classify patients depending on their risk of preec-
lampsia already at 19–24 weeks gestational age [26], and 
then to compare the results at 30–34 [27] and at 35–37 [28] 
weeks gestational age. Historically, the highest sensitivity 
and specificity have been achieved by combining physical 
(MAP) and imaging (UtA-PI) examinations with biochemical 
(sFlt-1/PlGF) tests. The possible clinical applications of sFlt-1, 
PlGF and sFlt-1/PlGF ratio test results are shown in Figure 2.
Figure 2. Possible applications of sFlt-1, PlGF and the sFlt-1/PlGF ratio in prediction, diagnosis and monitoring of preeclampsia
20–24, 30–34 and 35–37 weeks — across 
the population: sFlt-1, PlGF, MAP, UtA PI
Prediction and classication 
in preeclampsia development
Suspected preeclampsia
20–40 weeks — across 




20–34 weeks — in risk 
factor women: sFlt-1/PlGF
11–14 and 19–24 weeks — across 
the population: PlGF, MAP, UtA PI
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Our paper focuses on preeclampsia because most re-
ports on the usefulness of the sFlt-1/PlGF ratio as a diagnos-
tic tool have concentrated on this clinical syndrome. It must 
be emphasized, however, that the sFlt-1 and PlGF angiogen-
esis -related disease markers also demonstrate irregulari-
ties in other conditions related to placental hypoperfusion 
and ischemia. The markers show similar variation profiles 
in intrauterine growth restriction syndromes (IUGR) [29], 
and in some cases of placental abruption [30].
SUMMARY
Preeclampsia develops as a result of placental insuf-
ficiency. New angiogenesis markers sFlt-1 and PlGF pro-
vide an opportunity to predict, diagnose and monitor the 
status of placental angiogenesis abnormalities, including 
preeclampsia. According to present data, sFlt-1, PlGF and 
the sFlt-1/PlGF ratio permit the creation of a new model 
for preeclampsia management. The sFlt-1/PlGF ratio seems 
to be an especially valuable tool for use in clinical practice.
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